Disclosures for "Superiority of Immunotherapy to Benzodiazepines and No Treatment in Down Syndrome Regression Disorder"
-
Dr. Santoro has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Santoro has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Cycle Pharma.
-
Dr. Jafarpour has nothing to disclose.
-
Dr. Hayati Rezvan has nothing to disclose.
-
Dr. Khoshnood has nothing to disclose.
-
Natalie Boyd has nothing to disclose.
-
Benjamin Vogel has nothing to disclose.
-
Lina Nguyen has nothing to disclose.
-
Miss Kazerooni has nothing to disclose.
-
Dr. Spinazzi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis Pharmaceuticals. Dr. Spinazzi has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Saldivar & Associates. The institution of Dr. Spinazzi has received research support from NIH.
-
Dr. Anadani has nothing to disclose.
-
Dr. Fisher has nothing to disclose.
-
The institution of an immediate family member of Dr. Filipink has received research support from NIH . Dr. Filipink has received personal compensation in the range of $0-$499 for serving as a Author with Medlink.
-
Melanie Manning has nothing to disclose.
-
Catherine Franklin has nothing to disclose.
-
Dr. Quinn has nothing to disclose.
-
Dr. Rafii has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AC Immune. Dr. Rafii has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Keystone Bio. Dr. Rafii has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alzheon.